Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
384 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ulcerative Colitis - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Ulcerative Colitis - Pipeline Review, H2 2015', provides an overview of the Ulcerative Colitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ulcerative Colitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ulcerative Colitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Ulcerative Colitis Overview 12 Therapeutics Development 13 Pipeline Products for Ulcerative Colitis - Overview 13 Pipeline Products for Ulcerative Colitis - Comparative Analysis 14 Ulcerative Colitis - Therapeutics under Development by Companies 15 Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes 22 Ulcerative Colitis - Pipeline Products Glance 23 Late Stage Products 23 Clinical Stage Products 24 Early Stage Products 25 Unknown Stage Products 26 Ulcerative Colitis - Products under Development by Companies 27 Ulcerative Colitis - Products under Investigation by Universities/Institutes 32 Ulcerative Colitis - Companies Involved in Therapeutics Development 33 4D Pharma Plc 33 Advinus Therapeutics Ltd. 34 Ajinomoto Pharmaceuticals Co., Ltd. 35 Altheus Therapeutics, Inc. 36 Am-Pharma B.V. 37 Amgen Inc. 38 Arena Pharmaceuticals, Inc. 39 Astellas Pharma Inc. 40 Atlantic Healthcare Plc 41 Avaxia Biologics, Inc. 42 BioAtla, LLC 43 BioLineRx, Ltd. 44 Bionovis SA 45 Celgene Corporation 46 Cellceutix Corporation 47 Celltrion, Inc. 48 ChemoCentryx, Inc. 49 ChironWells GmbH 50 Chong Kun Dang Pharmaceutical Corp. 51 Cosmo Pharmaceuticals S.p.A 52 Dr. Falk Pharma GmbH 53 Effimune SAS 54 Eli Lilly and Company 55 Emergent BioSolutions Inc. 56 Enceladus Pharmaceuticals BV 57 enGene, Inc 58 Enterome Bioscience SA 59 Epirus Biopharmaceuticals, Inc. 60 Flexion Therapeutics, Inc. 61 Galapagos NV 62 Genentech, Inc. 63 Genor BioPharma Co., Ltd. 64 Gilead Sciences, Inc. 65 GW Pharmaceuticals Plc 66 Hetero Drugs Limited 67 iCo Therapeutics Inc. 68 Idera Pharmaceuticals, Inc. 69 InDex Pharmaceuticals AB 70 Innovate Biopharmaceuticals, Inc. 71 INOXIA Lifesciences GmbH 72 Intas Pharmaceuticals Ltd. 73 Invion Limited 74 Johnson & Johnson 75 Kaken Pharmaceutical Co., Ltd. 76 Kymab Limited 77 LIPID THERAPEUTICS GmbH 78 LTT Bio-Pharma Co., Ltd. 79 Mabion SA 80 Mabtech Limited 81 Medestea Research & Production S.p.A. 82 Momenta Pharmaceuticals, Inc. 83 Morphotek, Inc. 84 Mycenax Biotech Inc. 85 Oncobiologics, Inc. 86 Pfizer Inc. 87 Pluristem Therapeutics Inc. 88 ProtAb Ltd 89 Protagonist Therapeutics Inc. 90 Qu Biologics Inc. 91 Rebiotix Inc. 92 Receptos, Inc. 93 Sandoz International GmbH 94 Seres Therapeutics, Inc. 95 Sigmoid Pharma Limited 96 Stelic Institute & Co. 97 sterna biologicals Gmbh & Co KG 98 Synergy Pharmaceuticals, Inc. 99 Takeda Pharmaceutical Company Limited 100 Therapeutic Proteins International, LLC 101 Therapix Biosciences Ltd 102 Theravance Biopharma, Inc. 103 Tillotts Pharma AG 104 Trino Therapeutics Limited 105 Ventria Bioscience 106 Zyngenia, Inc. 107 Ulcerative Colitis - Therapeutics Assessment 108 Assessment by Monotherapy Products 108 Assessment by Combination Products 109 Assessment by Target 110 Assessment by Mechanism of Action 115 Assessment by Route of Administration 119 Assessment by Molecule Type 121 Drug Profiles 123 (mesalamine + N-acetylcysteine) - Drug Profile 123 abrilumab - Drug Profile 125 ABS-11 - Drug Profile 126 adalimumab biosimilar - Drug Profile 127 adalimumab biosimilar - Drug Profile 128 adalimumab biosimilar - Drug Profile 129 adalimumab biosimilar - Drug Profile 130 adalimumab biosimilar - Drug Profile 131 adalimumab biosimilar - Drug Profile 132 adalimumab biosimilar - Drug Profile 133 adalimumab biosimilar - Drug Profile 134 adalimumab biosimilar - Drug Profile 135 adalimumab biosimilar - Drug Profile 136 adalimumab biosimilar - Drug Profile 137 adalimumab biosimilar - Drug Profile 138 adalimumab biosimilar - Drug Profile 139 AJM-300 - Drug Profile 140 AKP-11 - Drug Profile 142 alicaforsen sodium - Drug Profile 144 Anatabine - Drug Profile 145 Antisense RNAi Oligonucleotide to Inhibit microRNA-214 for Ulcerative Colitis and Colon Cancer - Drug Profile 147 APD-334 - Drug Profile 148 apremilast - Drug Profile 149 ASP-3291 - Drug Profile 152 AVX-470 - Drug Profile 153 AW/EPO-002 - Drug Profile 155 AW/EPO-003 - Drug Profile 156 AW/EPOPD-01 - Drug Profile 157 AW/EPOPD-02 - Drug Profile 158 AW/EPOPD-06 - Drug Profile 159 bertilimumab - Drug Profile 160 BL-7040 - Drug Profile 162 brilacidin tetrahydrochloride - Drug Profile 164 budesonide - Drug Profile 166 CCX-507 - Drug Profile 169 CKD-506 - Drug Profile 170 cyclosporine CR - Drug Profile 171 D-9030 - Drug Profile 172 DIMS-0150 - Drug Profile 173 dolcanatide - Drug Profile 176 Drug to Inhibit Phospholipase A2 for Crohn's Disease and Ulcerative Colitis - Drug Profile 177 Drugs for Ulcerative Colitis - Drug Profile 178 EB-120 - Drug Profile 179 EFFI-7H - Drug Profile 180 EG-10 - Drug Profile 181 EG-12 - Drug Profile 182 enalaprilat - Drug Profile 183 ES-210 - Drug Profile 184 etrolizumab - Drug Profile 185 FX-003 - Drug Profile 187 GLPG-1205 - Drug Profile 188 golimumab biosimilar - Drug Profile 189 golimumab biosimilar - Drug Profile 190 golimumab biosimilar - Drug Profile 191 GS-5745 - Drug Profile 192 GWP-42003 - Drug Profile 194 hyaluronate sodium - Drug Profile 195 IAC VITA - Drug Profile 196 IMO-9200 - Drug Profile 198 infliximab - Drug Profile 199 infliximab biobetter - Drug Profile 202 infliximab biosimilar - Drug Profile 203 infliximab biosimilar - Drug Profile 206 infliximab biosimilar - Drug Profile 207 infliximab biosimilar - Drug Profile 209 infliximab biosimilar - Drug Profile 210 INN-108 - Drug Profile 211 INV-103 - Drug Profile 212 INV-88 - Drug Profile 214 KAG-308 - Drug Profile 215 KANAb-071 - Drug Profile 216 kPPF-1 - Drug Profile 217 KY-1006 - Drug Profile 218 lipidated tacrolimus - Drug Profile 219 LT-0011 - Drug Profile 220 LT-02 - Drug Profile 221 LY-3074828 - Drug Profile 222 mesalamine - Drug Profile 223 mesalamine - Drug Profile 224 mesalamine DR - Drug Profile 225 mesalamine ER - Drug Profile 226 mongersen - Drug Profile 228 Monoclonal Antibodies to Antagonize Metallothioneins for Ulcerative Colitis and Crohn's Disease - Drug Profile 229 Monoclonal Antibody for Autoimmune Diseases, Ulcerative Colitis, Crohn's Disease and Colorectal cancer - Drug Profile 230 Monoclonal Antibody to Inhibit Ang-2 and TNF-a for Ulcerative Colitis, Arthritis and Inflammatory Disease - Drug Profile 231 Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile 232 naltrexone hydrochloride - Drug Profile 234 NRG-4 - Drug Profile 235 ozanimod hydrochloride - Drug Profile 237 P-Dex - Drug Profile 239 peficitinib hydrobromide - Drug Profile 241 PF-00547659 - Drug Profile 243 PH-44 - Drug Profile 245 PH-46A - Drug Profile 246 PH-5 - Drug Profile 247 PNQ-201 - Drug Profile 248 prednisolone sodium phosphate - Drug Profile 249 Prozumab - Drug Profile 251 PTG-100 - Drug Profile 252 QBECO-SSI - Drug Profile 253 RBX-2660 - Drug Profile 256 Recombinant Human Alkaline Phosphatase - Drug Profile 258 Rosburix - Drug Profile 260 SB-012 - Drug Profile 261 SER-287 - Drug Profile 262 SER-301 - Drug Profile 263 Small Molecule to Agonize OP3 Receptor for Crohn's Disease and Ulcerative Colitis - Drug Profile 264 Small Molecule to Agonize S1PR1 for Ulcerative Colitis - Drug Profile 265 Small Molecule to Scavenge Nitric Oxide Radical for Ulcerative Colitis and Inflammation - Drug Profile 266 Small Molecules for Ulcerative Colitis and Crohn's Disease - Drug Profile 267 Small Molecules for Ulcerative Colitis and Crohn's Disease - Drug Profile 268 Small Molecules to Antagonize Integrin Alpha4Beta7 for Inflammatory Bowel Disease - Drug Profile 269 Small Molecules to Inhibit IL-13 for Ulcerative Colitis - Drug Profile 270 Small Molecules to Target IL-13 for Ulcerative Colitis - Drug Profile 271 Stem Cell Therapy for Inflammatory Bowel Disease - Drug Profile 272 STNM-01 - Drug Profile 273 Synthetic Peptides to Target IL-23R for Crohn's Disease and Ulcerative colitis - Drug Profile 274 TAK-114 - Drug Profile 275 TD-1473 - Drug Profile 277 tofacitinib - Drug Profile 278 TOP-1288 - Drug Profile 282 TP-10 - Drug Profile 283 ustekinumab - Drug Profile 284 VEDA-1209 - Drug Profile 287 vedolizumab - Drug Profile 288 VEN-120 - Drug Profile 290 Ulcerative Colitis - Recent Pipeline Updates 291 Ulcerative Colitis - Dormant Projects 359 Ulcerative Colitis - Dormant Projects 359 Ulcerative Colitis - Discontinued Products 363 Ulcerative Colitis - Product Development Milestones 364 Featured News & Press Releases 364 Appendix 374 Methodology 374 Coverage 374 Secondary Research 374 Primary Research 374 Expert Panel Validation 374 Contact Us 374 Disclaimer 375
List of Tables
Number of Products under Development for Ulcerative Colitis, H2 2015 22 Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H2 2015 23 Number of Products under Development by Companies, H2 2015 25 Number of Products under Development by Companies, H2 2015 (Contd..1) 26 Number of Products under Development by Companies, H2 2015 (Contd..2) 27 Number of Products under Development by Companies, H2 2015 (Contd..3) 28 Number of Products under Development by Companies, H2 2015 (Contd..4) 29 Number of Products under Development by Companies, H2 2015 (Contd..5) 30 Number of Products under Investigation by Universities/Institutes, H2 2015 31 Comparative Analysis by Late Stage Development, H2 2015 32 Comparative Analysis by Clinical Stage Development, H2 2015 33 Comparative Analysis by Early Stage Development, H2 2015 34 Comparative Analysis by Unknown Stage Development, H2 2015 35 Products under Development by Companies, H2 2015 36 Products under Development by Companies, H2 2015 (Contd..1) 37 Products under Development by Companies, H2 2015 (Contd..2) 38 Products under Development by Companies, H2 2015 (Contd..3) 39 Products under Development by Companies, H2 2015 (Contd..4) 40 Products under Investigation by Universities/Institutes, H2 2015 41 Ulcerative Colitis - Pipeline by 4D Pharma Plc, H2 2015 42 Ulcerative Colitis - Pipeline by Advinus Therapeutics Ltd., H2 2015 43 Ulcerative Colitis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H2 2015 44 Ulcerative Colitis - Pipeline by Altheus Therapeutics, Inc., H2 2015 45 Ulcerative Colitis - Pipeline by Am-Pharma B.V., H2 2015 46 Ulcerative Colitis - Pipeline by Amgen Inc., H2 2015 47 Ulcerative Colitis - Pipeline by Arena Pharmaceuticals, Inc., H2 2015 48 Ulcerative Colitis - Pipeline by Astellas Pharma Inc., H2 2015 49 Ulcerative Colitis - Pipeline by Atlantic Healthcare Plc, H2 2015 50 Ulcerative Colitis - Pipeline by Avaxia Biologics, Inc., H2 2015 51 Ulcerative Colitis - Pipeline by BioAtla, LLC, H2 2015 52 Ulcerative Colitis - Pipeline by BioLineRx, Ltd., H2 2015 53 Ulcerative Colitis - Pipeline by Bionovis SA, H2 2015 54 Ulcerative Colitis - Pipeline by Celgene Corporation, H2 2015 55 Ulcerative Colitis - Pipeline by Cellceutix Corporation, H2 2015 56 Ulcerative Colitis - Pipeline by Celltrion, Inc., H2 2015 57 Ulcerative Colitis - Pipeline by ChemoCentryx, Inc., H2 2015 58 Ulcerative Colitis - Pipeline by ChironWells GmbH, H2 2015 59 Ulcerative Colitis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 60 Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2015 61 Ulcerative Colitis - Pipeline by Dr. Falk Pharma GmbH, H2 2015 62 Ulcerative Colitis - Pipeline by Effimune SAS, H2 2015 63 Ulcerative Colitis - Pipeline by Eli Lilly and Company, H2 2015 64 Ulcerative Colitis - Pipeline by Emergent BioSolutions Inc., H2 2015 65 Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H2 2015 66 Ulcerative Colitis - Pipeline by enGene, Inc, H2 2015 67 Ulcerative Colitis - Pipeline by Enterome Bioscience SA, H2 2015 68 Ulcerative Colitis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 69 Ulcerative Colitis - Pipeline by Flexion Therapeutics, Inc., H2 2015 70 Ulcerative Colitis - Pipeline by Galapagos NV, H2 2015 71 Ulcerative Colitis - Pipeline by Genentech, Inc., H2 2015 72 Ulcerative Colitis - Pipeline by Genor BioPharma Co., Ltd., H2 2015 73 Ulcerative Colitis - Pipeline by Gilead Sciences, Inc., H2 2015 74 Ulcerative Colitis - Pipeline by GW Pharmaceuticals Plc, H2 2015 75 Ulcerative Colitis - Pipeline by Hetero Drugs Limited, H2 2015 76 Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H2 2015 77 Ulcerative Colitis - Pipeline by Idera Pharmaceuticals, Inc., H2 2015 78 Ulcerative Colitis - Pipeline by InDex Pharmaceuticals AB, H2 2015 79 Ulcerative Colitis - Pipeline by Innovate Biopharmaceuticals, Inc., H2 2015 80 Ulcerative Colitis - Pipeline by INOXIA Lifesciences GmbH, H2 2015 81 Ulcerative Colitis - Pipeline by Intas Pharmaceuticals Ltd., H2 2015 82 Ulcerative Colitis - Pipeline by Invion Limited, H2 2015 83 Ulcerative Colitis - Pipeline by Johnson & Johnson, H2 2015 84 Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2015 85 Ulcerative Colitis - Pipeline by Kymab Limited, H2 2015 86 Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H2 2015 87 Ulcerative Colitis - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015 88 Ulcerative Colitis - Pipeline by Mabion SA, H2 2015 89 Ulcerative Colitis - Pipeline by Mabtech Limited, H2 2015 90 Ulcerative Colitis - Pipeline by Medestea Research & Production S.p.A., H2 2015 91 Ulcerative Colitis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2015 92 Ulcerative Colitis - Pipeline by Morphotek, Inc., H2 2015 93 Ulcerative Colitis - Pipeline by Mycenax Biotech Inc., H2 2015 94 Ulcerative Colitis - Pipeline by Oncobiologics, Inc., H2 2015 95 Ulcerative Colitis - Pipeline by Pfizer Inc., H2 2015 96 Ulcerative Colitis - Pipeline by Pluristem Therapeutics Inc., H2 2015 97 Ulcerative Colitis - Pipeline by ProtAb Ltd, H2 2015 98 Ulcerative Colitis - Pipeline by Protagonist Therapeutics Inc., H2 2015 99 Ulcerative Colitis - Pipeline by Qu Biologics Inc., H2 2015 100 Ulcerative Colitis - Pipeline by Rebiotix Inc., H2 2015 101 Ulcerative Colitis - Pipeline by Receptos, Inc., H2 2015 102 Ulcerative Colitis - Pipeline by Sandoz International GmbH, H2 2015 103 Ulcerative Colitis - Pipeline by Seres Therapeutics, Inc., H2 2015 104 Ulcerative Colitis - Pipeline by Sigmoid Pharma Limited, H2 2015 105 Ulcerative Colitis - Pipeline by Stelic Institute & Co., H2 2015 106 Ulcerative Colitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2015 107 Ulcerative Colitis - Pipeline by Synergy Pharmaceuticals, Inc., H2 2015 108 Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 109 Ulcerative Colitis - Pipeline by Therapeutic Proteins International, LLC, H2 2015 110 Ulcerative Colitis - Pipeline by Therapix Biosciences Ltd, H2 2015 111 Ulcerative Colitis - Pipeline by Theravance Biopharma, Inc., H2 2015 112 Ulcerative Colitis - Pipeline by Tillotts Pharma AG, H2 2015 113 Ulcerative Colitis - Pipeline by Trino Therapeutics Limited, H2 2015 114 Ulcerative Colitis - Pipeline by Ventria Bioscience, H2 2015 115 Ulcerative Colitis - Pipeline by Zyngenia, Inc., H2 2015 116 Assessment by Monotherapy Products, H2 2015 117 Assessment by Combination Products, H2 2015 118 Number of Products by Stage and Target, H2 2015 120 Number of Products by Stage and Mechanism of Action, H2 2015 125 Number of Products by Stage and Route of Administration, H2 2015 129 Number of Products by Stage and Molecule Type, H2 2015 131 Ulcerative Colitis Therapeutics - Recent Pipeline Updates, H2 2015 300 Ulcerative Colitis - Dormant Projects, H2 2015 368 Ulcerative Colitis - Dormant Projects (Contd..1), H2 2015 369 Ulcerative Colitis - Dormant Projects (Contd..2), H2 2015 370 Ulcerative Colitis - Dormant Projects (Contd..3), H2 2015 371 Ulcerative Colitis - Discontinued Products, H2 2015 372
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
